Capsulized FMT
ADVERSE EFFECTS
All patients provided written informed consent. Authorized physicians administered FMT in a monitored clinical setting. Patients should fast for at least 8 hours prior to FMT. The frozen capsules were removed to room temperature before use. After administration, patients were onwards observed for adverse effects. Enrolled patients received three FMT treatments (once every two days) in a single dose of 30 capsules. The donors were randomly assigned to enrolled patients. Each patient received two donors flora at least. Patients were followed up for 12 weeks after FMT treatment, and their stool samples were collected at weeks 0, 1, 4, and 12. At baseline (W0, before taking FMT) and W12, coloscopies were taken to assess patients’ response to FMT. Maintenance therapy was required in this study according to their usage before enrollment: 1) 5-ASA or SASP- kept using the stable dosage of 5-ASA or SASP; 2) prednisone- with a mandatory taper of 5 mg (>10mg/d) or 2.5mg (≤10mg/d) per week. The weekly time points were abbreviated as W0 (baseline, week 0), W1 (week 1), W4 (week 4), and W12 (week 12).